These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Ogawa Y; Okamoto S; Kuwana M; Mori T; Watanabe R; Nakajima T; Yamada M; Mashima Y; Tsubota K; Oguchi Y Cornea; 2001 May; 20(4):430-4. PubMed ID: 11333336 [TBL] [Abstract][Full Text] [Related]
4. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Yanagisawa R; Katsuyama Y; Shigemura T; Saito S; Tanaka M; Nakazawa Y; Sakashita K; Shiohara M; Koike K Bone Marrow Transplant; 2011 Jan; 46(1):90-7. PubMed ID: 20383212 [TBL] [Abstract][Full Text] [Related]
5. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation. Butts AR; Brown VT; McBride LD; Bolaños-Meade J; Bryk AW J Oncol Pharm Pract; 2016 Apr; 22(2):275-83. PubMed ID: 25802301 [TBL] [Abstract][Full Text] [Related]
6. A case report: acute pancreatitis associated with tacrolimus in kidney transplantation. Xu J; Xu L; Wei X; Li X; Cai M BMC Nephrol; 2019 Jun; 20(1):209. PubMed ID: 31174507 [TBL] [Abstract][Full Text] [Related]
7. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223 [TBL] [Abstract][Full Text] [Related]
8. [Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation]. Hosonuma R; Fujiwara S; Sasazaki M; Hirata Y; Yamamoto C; Uesawa M; Oh I; Matsuyama T; Mori M; Ozawa K; Muroi K Rinsho Ketsueki; 2012 Apr; 53(4):469-71. PubMed ID: 22687983 [TBL] [Abstract][Full Text] [Related]
9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738 [TBL] [Abstract][Full Text] [Related]
10. Tacrolimus clearance is age-dependent within the pediatric population. Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564 [TBL] [Abstract][Full Text] [Related]
11. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426 [TBL] [Abstract][Full Text] [Related]
12. Fatal cerebral hemorrhage associated with cyclosporin-A/FK506-related encephalopathy after allogeneic bone marrow transplantation. Mori A; Tanaka J; Kobayashi S; Hashino S; Yamamoto Y; Ota S; Asaka M; Imamura M Ann Hematol; 2000 Oct; 79(10):588-92. PubMed ID: 11100753 [TBL] [Abstract][Full Text] [Related]
13. [Myelodysplastic syndrome with cyclosporine A-induced encephalopathy presenting with a mass effect on the right basal ganglia after cord blood transplantation]. Koh H; Yamane T; Nakane T; Takeoka Y; Sakamoto E; Kanashima H; Nakamae M; Nakamae H; Koh KR; Mochizuki K; Hayashi N; Hino M Rinsho Ketsueki; 2006 Dec; 47(12):1539-43. PubMed ID: 17233473 [TBL] [Abstract][Full Text] [Related]
14. [Optimal therapeutic concentration of tacrolimus in adult patients undergoing reduced-intensity cord blood transplantation]. Nasu I; Ito T; Ino K; Minowa M; Furusawa M; Okuno Y; Uchida Y; Ishiwata K; Nakano N; Tsuji M; Takagi S; Yamamoto H; Matsuno N; Mori Y; Uchida N; Masuoka K; Wake A; Makino S; Miyakoshi S; Taniguchi S; Hayashi M Gan To Kagaku Ryoho; 2011 Feb; 38(2):249-53. PubMed ID: 21372630 [TBL] [Abstract][Full Text] [Related]
15. Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis. Najera JE; Alousi A; De Lima M; Ciurea SO Bone Marrow Transplant; 2013 Jan; 48(1):157-8. PubMed ID: 22705799 [No Abstract] [Full Text] [Related]
16. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. Ohashi Y; Minegishi M; Fujie H; Tsuchiya S; Konno T Bone Marrow Transplant; 1997 Mar; 19(6):625-7. PubMed ID: 9085743 [TBL] [Abstract][Full Text] [Related]
17. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Conrotto D; Carrozzo M; Ubertalli AV; Gandolfo S; Giaccone L; Boccadoro M; Bruno B Transplantation; 2006 Oct; 82(8):1113-5. PubMed ID: 17060865 [No Abstract] [Full Text] [Related]
18. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Woo M; Przepiorka D; Ippoliti C; Warkentin D; Khouri I; Fritsche H; Körbling M Bone Marrow Transplant; 1997 Dec; 20(12):1095-8. PubMed ID: 9466284 [TBL] [Abstract][Full Text] [Related]
19. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. Hedayat S; Kershner RP; Su G J Biopharm Stat; 1996 Nov; 6(4):411-24. PubMed ID: 8969977 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation. Tamaki H; Kawakami M; Ikegame K; Iio K; Harada Y; Hatanaka K; Oka Y; Kawase I; Ogawa H Int J Hematol; 2004 Oct; 80(3):291-4. PubMed ID: 15540907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]